Home

Casp6 (human)

Overview Casp6 Involved in the activation cascade of caspases responsible for apoptosis execution. Cleaves poly(ADP-ribose) polymerase in vitro, as well as lamins. Overexpression promotes programmed cell death. Heterotetramer that consists of two anti-parallel arranged heterodimers, each one formed by a 18 kDa (p18) and a 11 kDa (p11) subunit. Interacts with BIRC6/bruce. Activation is suppressed by phosphorylation at Ser-257. Belongs to the peptidase C14A family. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB. Protein type: Protease; EC 3.4.22.-; EC 3.4.22.59; Apoptosis Cellular Component: nucleoplasm; cytoplasm; nucleolus; cytosol; nucleus Molecular Function: protein binding; cysteine-type endopeptidase activity; cysteine-type peptidase activity Biological Process: lens development in camera-type eye; positive regulation of retinal cell programmed cell death; apoptosis; acute inflammatory response to non-antigenic stimulus; response to testosterone stimulus; proteolysis; response to organic nitrogen; response to estradiol stimulus; response to hydrogen peroxide; response to heat; response to cytokine stimulus; positive regulation of neuron apoptosis; induction of apoptosis; response to glucose stimulus; response to gamma radiation; response to iron ion; cell structure disassembly during apoptosis Reference #:  P55212 (UniProtKB) Alt. Names/Synonyms: Apoptotic protease Mch-2; CASP-6; CASP6; caspase 6, apoptosis-related cysteine peptidase; caspase 6, apoptosis-related cysteine protease; Caspase-6; Caspase-6 subunit p11; Caspase-6 subunit p18; MCH2 Gene Symbols: CASP6 Molecular weight: 33,310 Da Basal Isoelectric point: 6.46  Predict pI for various phosphorylation states CST Pathways:  Apoptosis  |  Death Receptor Signaling  |  ErbB/HER Signaling  |  Inhibition of Apoptosis Protein-Specific Antibodies or siRNAs from Cell Signaling Technology®

Select Structure to View Below Casp6 1MI9 - A=34-175, B=198-290 (human) 2WDP - A/B/C/D=1-293 (human) 3K7E - A/D/C/B=24-293 (human) 3NKF - A/D/C/B=24-293 (human) 3NR2 - A/B=24-293 (human) 3OD5 - A/B=24-293 (human) 3P45 - F/N/L/J/P/B/H/D=193-293 K/E/M/C/A/O/I/G=1-179 (human) 3P4U - A/C=24-179 D/B=193-293 (human) 3QNW - A/E/C/G=24-179 F/B/H/D=194-293 (human) 3S70 - A/C=24-293 (human) 3S8E - F/A/E/B/H/C/D/G=24-293 (human) 3V6L - A/B=21-293 (human) 3V6M - F/A/J/D/C/I/G/B=24-293 (human) 4EJF - A/D/C/B=24-293 (human) 4FXO - A/D/C/B=1-293 (human) 4HVA - A/B=24-293 (human)

STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  RCSB PDB 1MI9 2WDP 3K7E 3NKF 3NR2 3OD5 3P45 3P4U 3QNW 3S70 3S8E 3V6L 3V6M 4EJF 4FXO 4HVA  |  ENZYME 3.4.22.- 3.4.22.59  |  Phospho3D  |  DISEASE  |  Source  |  UCSD-Nature  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  Ensembl Gene

	Modification Sites and Domains	Show Modification Legend
Click here to view phosphorylation modifications only

	Modification Sites in Parent Protein, Orthologs, and Isoforms	Show Modification Legend

SS  SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.	MS  MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.			human
0	1		K36-a	EMFDPAEkYKMDHRR
0	1		S79-p	DNLTRRFsDLGFEVK
0	1		K144-u	QTLTGLFkGDKCHSL
3	0		S257-p	TLVNRKVsQRRVDFC
0	1		K273-a	DPSAIGKkQVPCFAS
0	1		K284-a	CFASMLTkkLHFFPK
0	1		K285-a	FASMLTkkLHFFPKS

	mouse
Q19	EVFDPAEQYKMDHKR
S62-p	DNLTRRFsDLGFEVK
K127	QTLTGLFKGDKCQSL
S239	TLVNRKVSQRRVDFC
K255	DPDAIGKKQVPCFAS
K266	CFASMLTKKLHFCPK
K267	FASMLTKKLHFCPKP

	rat
Q19	EVLDPAEQYKMDHKR
S62	DNPTRRFSELGFEVK
K127	QTLTGLFKGDKCQSL
S240	TLVNRKVSQRRVDFC
K256	DPGAIGKKQVPCFAS
K267	CFASMLTKKLHFCPK
K268	FASMLTKKLHFCPKP

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E Produced by 3rd Millennium  |  Design by Digizyme ©2003-2013 Cell Signaling Technology, Inc.